Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (10 issues)
Down 1.32% to $44.03. The mean-reversion bet never turned: guidance cut, competition, litigation, -31% in three months and 42% below the 200-day. Wrong thesis — closing the long, out.
Up 3.7% to $44.62 as devices rallied on Abbott's print — the left-side repair finally looks right-sided; holding
Up 1.0% to $43.04 in week N of the left-side repair — a newsless position is a good position; holding
Down 0.3% to $44.65 — the left-side repair keeps grinding; patience is this position's only cost, holding
Down 0.5%, idling half a length under the 20-day; patience for the left-side repair remains sufficient — holding
Up 0.4%, steadying; the left-side repair thesis stands — reclaiming the 20-day ($45.20) is confirmation one
Down 1.1%, trimming the left-side entry's gains; the repair thesis is unchanged, holding
+1.6%, long +5.2%; the left-side buy is paying, hold for repair
Medtech -1.2%, long +3.6%; left-side buy after a 53% down year, hold for a bounce
RSI 28 with EPS +74.7% — a rare fundamentals/price divergence worth digging into